Hayley Burgess SVP, Inovalon, touches on Specialty pharmacies grappling with surging drug complexity and costs while ...

Michael O' Rurke , CEO Re-Vana Therapeutics, discusses positioning Re-Vana as a long-term platform partner by leveraging its ...

PE: How can teams reduce patient burden without weakening their science? Schwab: Number one is lean trial design. We should ...

32 Biosciences revealed its plan to launch a $40 million Series A at this year’s J.P Morgan Healthcare conference, to advance ...

Johnson & Johnson continues its $55 billion investment in U.S. operations (first announced back in 2025), targeting ...

In the third part of her conversation with PharmExec, Trialynx founder and CEO Angela Schwab discusses the causes and ...

In today’s Pharmaceutical Executive Daily, the FDA moves to limit regulation of non-medical fitness wearables, industry ...

The "Pharmaceutical Current Good Manufacturing Practices (CGMPs) for the 21st Century--A Risk Based Approach" initiative was ...

“Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior ...

A new unified approach to process analytical technologies from Recipharm Advanced Bio aims to replace fragmented, off-line testing with integrated real-time analytics—cutting development and release ...

Vanda Pharmaceuticals announced it received a decision letter from the FDA’s Center for Drug Evaluation and Research (CDER) stating that the supplemental New Drug Application (NDA) for Hetlioz ...

Eli Lilly and Company and Ventyx Biosciences entered into a definitive agreement under which Eli Lilly will acquire Ventyx in ...